CytoDyn Signs Agreement With Amarex Clinical Research LLC To Prepare Two Phase 2b Clinical Trial Protocols To Explore Two Additional Therapeutic Indications For PRO 140
VANCOUVER, Wash.--(BUSINESS WIRE)--CytoDyn Inc. (OTCQB: CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, announced today that the Company plans to expand its clinical development program for PRO 140 and signed an agreement with Amarex Clinical Research LLC to prepare two Phase 2b clinical trial protocols to explore two additional therapeutic indications for its lead product candidate. One of the new protocols is expected to be completed in the first quarter of 2014 and the second protocol early in the second quarter of 2014. After submission of the Phase 2b clinical trial protocols to the U.S. Food and Drug Administration (FDA), the Company and Amarex will work with the FDA to obtain approval to commence the trials.
Help employers find you! Check out all the jobs and post your resume.